Transplant drug for older patients with severe aplastic anemia
Treatments studied
Part of Blood & lymphatic clinical trials.
This study looks at using a chemotherapy drug called thiotepa as part of the pre-transplant conditioning (treatment to prepare the body) for older adults with severe aplastic anemia who are getting a transplant from a half-matched family donor. The goal is to see how well this approach works for people aged 50 and older.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 50 years old or older at the time of the transplant.
- You must have a diagnosis of severe or very severe aplastic anemia, a condition where the bone marrow fails to make enough blood cells.
- You must be planning to receive a transplant from a half-matched family donor (also called a haploidentical donor).
- Your transplant conditioning regimen (the pre-transplant treatment) must include a medicine called thiotepa.
- Your medical records must have the necessary health and transplant information.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new combination of drugs to prepare older patients (40–60 years old) with severe aplastic anemia for a stem cell transplant from a half-matched donor. The goal is to make the transplant safer and more effective for this age group.
This Phase 2 study tests a bone marrow transplant from a closely matched related donor, plus medicine after the transplant to help prevent immune complications. It may be an option if you have severe aplastic anemia and meet specific health and lab requirements.
This trial tests a stem cell transplant using a milder conditioning regimen and a drug called post-transplant cyclophosphamide to treat severe aplastic anemia and other acquired bone marrow failure conditions. The goal is to help patients achieve a functioning donor bone marrow with fewer side effects.
This trial tests whether adding a drug called thiotepa to the usual chemotherapy (busulfan and fludarabine) before a half-matched stem cell transplant can safely and effectively treat older adults (55–70) with high-risk AML.
This trial tests a gentler conditioning regimen (using lower-dose radiation) before a stem cell transplant for people aged 50 and older with aplastic anemia. The goal is to make the transplant safer and more tolerable for older patients.
This trial tests a special combination of chemotherapy drugs (called a conditioning regimen) given before a half-matched stem cell transplant for older adults with acute myeloid leukemia (AML) in their first remission. The goal is to make the transplant safer and more effective for people aged 55 to 75.
Hear when a new Severe Aplastic Anemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.